Advances in antifungal therapy

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 361-379

  Sable, Carole A ^a   Strohmaier, Kim M ^b   Chodakewitz, Jeffrey A ^b  

^a Novexel SA   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

glucan; Echinocandins; Galactomannan; Posaconazole; Voriconazole

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASTEMIZOLE; BETA GLUCAN; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; ERGOT ALKALOID; GALACTOMANNAN; METHADONE; MICAFUNGIN; NEVIRAPINE; NIFEDIPINE; OMEPRAZOLE; PHENYTOIN; PIMOZIDE; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; TACROLIMUS; TERFENADINE; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ABNORMAL VISION; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPERGILLOSIS; BILIRUBIN BLOOD LEVEL; CANDIDEMIA; CHILL; CLINICAL TRIAL; COLOR VISION; DIAGNOSTIC TEST; DIARRHEA; DRUG DOSE INCREASE; DRUG INDICATION; DRUG TOLERABILITY; ENZYME IMMUNOASSAY; FEVER; HALLUCINATION; HEADACHE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPOKALEMIA; IMMUNE DEFICIENCY; LIVER FUNCTION TEST; MONOTHERAPY; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHLEBITIS; PHOTOPHOBIA; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING;

ADULT; ANTIFUNGAL AGENTS; CHILD; ECHINOCANDINS; HUMANS; MYCOSES; TRIAZOLES;

EID: 39649113871     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.062906.071602     Document Type: Review

References (99)

1. Marr K, Carter R, Grippa F, et al. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-17
2. Cappelletty D, Eiselstein-McKitrick K. 2007. The echinocandins. Pharmacotherapy 27:369-88
3. Wagner C, Graninger W, Presterl E, et al. 2006. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 78:161-77
4. Morrisson VA. 2006. Echinocandin antifungals: review and update. Expert Rev. Anti-Infect. Ther. 4:325-42
5. CANCIDAS® (caspofungin acetate) for injection. Prescribing Information, Feb. 2005. Merck & Co., Inc., Whitehouse Station, NJ. Available at http://www.merck. com/product/usa/pi_circulars/c/cancidas/cancidas_pi. pdf
6. Villaneuva A, Gotuzzo E, Arathoon EG, et al. 2002. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113:294-99
7. Mora-Duarte J, Betts R, Rotstein C, et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-29
8. Cornely O, Lasso M, Betts R, et al. 2007. Caspofungin for the treatment of less common forms of invasive candidiasis. J. Antimicrob. Chemother. 60:363-69
9. Maertens J, Raad I, Petrikkos G, et al. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-71
10. Kartsonis NA, Saah AJ, Lipka CJ, et al. 2005. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J. Infect. 50:196-205
11. Walsh TJ, Teppler H, Donowitz GR, et al. 2004. Caspofungin versus liposomal amphotericin B for empirical antifngal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351:1391-402
12. MYCAMINE® (micafungin sodium) for injection. Prescribing Information, June 2006. Astellas Pharma US, Inc., Deerfield, IL. Available at http://www.astellas.us/docs/mycamine.pdf
13. de Wet N, Bester AJ, Viljoen JJ, et al. 2005. A randomized, double blind, comparative trial of micafungin (FK463) vs fluconazole for the treatment of oesophageal candidiasis. Aliment. Pharmacol. Ther. 21:899-907
14. van Burik JA, Ratanatharathorn V, Stepan DE, et al. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39:1407-16
15. Pappas PG, Rotstein CM, Betts RF, et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-93
16. Denning DW, Marr KA, Lau WM, et al. 2006. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. 53:337-49
17. ERAXIS™ (anidulafungin) for injection. Prescribing Information, Mar. 2006. Pfizer Inc., New York, NY. Available at http://media.pfizer.com/ files/products/uspi_eraxis.pdf
18. Krause DS, Simjee AE, van Rensburg C, et al. 2004. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39:770-75
19. Reboli AC, Rotstein C, Pappas PG, et al. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-82
20. Katiyar S, Pfaller M, Edlind T. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50(8):2892-94
21. Balashov S, Park S, Perlin D. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50(6):2058-63
22. Park S, Kely R, Kahn N, et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49(8):3264-73
23. Niimi K, Maki K, Ikeda F, et al. 2006. Overexpression of Candida albicans CDR1, CDR2 or MDR1 does not produce signifigant changes in echinocandin susceptibility. Antimicrob. Agents Chemother. 50(4):4148-55
24. Walsh TJ, Adamson PC, Seibel NL, et al. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49:4536-45
25. Jafri H, Zaoutis T, Keller N, et al. 2006. Prospective, multicenter study of caspofungin (CAS) for treatment (Rx) of documented fungal infections in pediatric patients (ped pts). Program Abstr. 46th Intersci. Conf. Antimicrob. Agents and Chemother., Abstr. G-873a. Washington, DC: Am. Soc. Microbiol.
26. Seibel NL, Schwart C, Arrieta A, et al. 2005. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49:3317-24
27. Heresi GP, Gerstmann DR, Reed MD, et al. 2006. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr. Infect. Dis. J. 25:1110-15
28. Arrieta AC, Telles Filho F, Berezin E, et al. 2006. A randomized, double-blind trial comparing micafungin (MCFG) and liposomal amphotericin B (L-AMB) in pediatric patients with invasive candidiasis (IC). Program Abstr. 46th Intersci. Conf. Antimicrob. Agents and Chemother., Abstr. M-1308b. Washington, DC: Am. Soc. Microbiol.
29. Flynn PM, Seibel N, Arrieta A, et al. 2006. Treatment of invasive aspergillosis (IA) in pediatric patients (pts) with micafungin (MICA) alone or in combination with other systemic antifungal agents. Program Abstr. 46th Intersci. Conf. Antimicrob. Agents and Chemother., Abstract M-891. Washington, DC: Am. Soc. Microbiol.
30. Benjamin DK, Driscoll T, Seibel NL, et al. 2006. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50:632-38
31. Scott LJ, Simpson D. 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269-98
32. Kofla G, Ruhnke M. 2005. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin. Pharmacother. 6:1215-29
33. Groll AH, Walsh TJ. 2005. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti Infect. Ther. 3:467-87
34. Keating GM. 2005. Posaconazole. Drugs 65:1553-67
35. VFEND® (voriconazole) I.V., tablets, and oral suspension. Prescribing Information, Mar. 2006. Pfizer Inc., New York, NY Available at http://media.pfizer.com/files/products/uspi_vfend.pdf
36. Ally R, Schurmann D, Kreisel W, et al. 2001. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33:1447-54
37. Kullberg BJ, Sobel JD, Ruhnke M, et al. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised noninferiority trial. Lancet 366:1435-42
38. Herbrecht R, Denning DW, Patterson TF, et al. 2002. Voriconazole versus amphotericin B for primary therapy in invasive aspergillosis. N. Engl. J. Med. 347:408-15
39. Schwartz S, Ruhnke M, Ribaud P, et al. 2005. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106:2641-45
40. Mouas H, Lutsar I, Dupont B, et al. 2005. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin. Infect. Dis. 40:1141-47
41. Walsh TJ, Papas P, Winston DJ, et al. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-34
42. NOXAFIL® (posaconazole) oral suspension. Prescribing Information, Oct. 2006. Schering Corp., Kenilworth, NJ. Available at http://www.spfiles. com/pinoxafil.pdf
43. Vazquez JA, Skiest DJ, Nieto L, et al. 2006. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. 42:1179-86
44. Ullmann AJ, Lipton JH, Vesole DH, et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-47
45. Cornely OA, Maertens J, Winston DJ, et al. 2007. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-59
46. Walsh TJ, Raad I, Patterson TF, et al. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12
47. van Burik JH, Hare RS, Solomon HF, et al. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:e61-65
48. Anderson J. 2005. Evolution of antifungal drug resistance: mechanisms and pathogen fitness. Microbiology 3:547-56
49. Sanguinetti M, Posteraro B, Fiori B, et al. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49:668-79
50. Sanglard D. 2002. Resistance of human fungal pathogens to antifungal drugs. Curr. Opin. Microbiol. 5:79-85
51. Sanglard D. 2003. Resistance and tolerance mechanisms to antifungal drugs in fungal pathogens. Mycologist 17:74-78
52. Wakieć R, Prasad R, Morschhäuser J, et al. 2006. Voriconazole and multidrug resistance in Candida albicans. Mycoses 50:109-15
53. Walsh TJ, Karlsson MO, Driscoll T, et al. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-72
54. Walsh TJ, Lutsar I, Driscoll T, et al. 2002. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21:240-48
55. Krishna G, Sansone-Parsons A, Martinho M, et al. 2007. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 51:812-18
56. Ganesan LT, Manavathu EK, Cutright JL, et al. 2004. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Eur. Soc. Clin. Microbiol. Infect. Dis. 10:961-66
57. Lupetti A, Dansei R, Van 't Wout J, et al. 2002. Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opin. Invest. Drugs. 11:309-18
58. Pappas P. 2004. Immunotherapy for invasive fungal infections: from bench to bedside. Drug Resist Updates 7:3-10
59. Hughes W, Armstrong D, Bodey G, et al. 2002. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34:730-51
60. Ozer H, Armitage J, Bennett C, et al. 2000. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J. Clin. Oncol. 18:3558-85
61. Burnie J, Carter T, Hodgetts S, et al. 2006. Fungal heat-shock proteins in human disease. FEMS Microbiol. Rev. 30(1):53-88
62. Pachl J, Svoboda P, Jacobs F, et al. 2006. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42:1404-13
63. Herbrecht R, Fohrer C, Nivoix Y. 2006. Letter to the editor: Mycograb for the treatment of invasive candidiasis. Clin. Infect. Dis. 43:1083
64. Mahfouz T, Anaissie E. 2003. Prevention of fungal infections in the immunocompromised host. Curr. Opin. Invest. Drugs. 4:974-90
65. National Comprehensive Cancer Network Prevention and Treatment of Cancer-Related Infections Panel Members. 2007. NCCN practice guidelines in oncology: prevention and treatment of cancer-related infections V.1.2007. http://www.nccn.org/professionals/physician_gls/default.asp
66. Maertens J, Theunissen K, Verhoef G, et al. 2005. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis. 41:1242-50
67. Cordonnier C, Pautas C, Maury S, et al. 2006. Empirical versus pre-emptive antifungal therapy in high-risk febrile neutropenic patients: a prospective randomized study. Presented at Am. Soc. Hematol. Annu. Meet. Expo., 48th, Orlando, FL
68. Schwarzinger M, Beauchamp C, Maury S, et al. 2006. Empirical versus pre-emptive antifungal therapy in high-risk febrile neutropenic patients: an economic analysis. Presented at Am. Soc. Hematol. Annu. Meet. Expo., 48th, Orlando, FL
69. Mukherjee PJ, Sheehan DJ, Hitchcock CA, et al. 2005. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18:163-94
70. Baddley JW, Pappas PG. 2005. Antifungal combination therapy: clinical potential. Drugs 65:1461-80
71. Rex JH, Pappas PG, Karchmer AW, et al. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36:1221-28
72. Aliff TB, Maslak PG, Jurcic JG, et al. 2003. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97:1025-32
73. Kontoyiannis DP, Hachem R, Lewis RE, et al. 2003. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292-99
74. Marr KA, Boeckh M, Carter RA, et al. 2004. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39:797-802
75. Maertens J, Glasmacher A, Herbrecht R, et al. 2006. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:2888-97
76. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. 2003. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J. Clin. Microbiol. 41:2184-86
77. Herbrecht R, Letscher-Bru V, Oprea C, et al. 2002. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 20:1898-906
78. Sulahian A, Boutboul F, Ribaud P, et al. 2001. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 91:311-18
79. Maertens J, Van Eldere J, Verhaegen J, et al. 2002. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J. Infect. Dis. 186:1297-306
80. Wheat L. 2003. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl. Infect. Dis. 5:158-66
81. Verweij P, Mennink-Kersten M. 2006. Issues with galactomannan testing. Med. Mycol. 44:S179-83
82. Marr K, Balajee A, McLaughlin L, et al. 2004. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J. Infect. Dis. 190:641-49
83. de Pauw BE, Patterson TF. 2005. Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed? Clin. Infect. Dis. 41:S377-80
84. Platelia Aspergillus EIA Product Sheet, Bio-Rad Laboratories, Inc., Redmond, WA. Available at http://www.bio-rad.com/cmc_upload/Literature/ 57083/J-115_Asperfillus.pdf
85. Pfeiffer C, Fine J, Safdar N. 2006. Diagnosis of invasive aspergillosis usinga galactomannan assay: a meta-analysis. Clin. Infect. Dis. 42:1417-27
86. Kwak E, Husain S, Obman A, et al. 2004. Efficacy of galactomannan antigen in the platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J. Clin. Microbiol. 42:435-38
87. Husain S, Kwak E, Obman A, et al. 2004. Prospective assessment of Platelia™ Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am. J. Transpl. 4:796-802
88. Mennink-Kersten M, Donnelly J, Verweij P. 2004. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet 4:349-57
89. Aubry A, Porcher R, Bottero J, et al. 2006. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with β-lactam antibiotics in patients with hematological disorders. J. Clin. Microbiol. 44:389-94
90. Herbrecht R, Letscher-Bru V, Oprea C, et al. 2002. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 20:1898-906
91. FUNGITELL™ instructions for use. 2004. Associates of Cape Cod, Inc., East Falmouth, MA. Available at http://www.acciusa.com/pdfs/ fungitell_insert.pdf
92. Ostrosky-Zeichner L, Alexander B, Kett D, et al. 2005. Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41:654-59
93. Odabasi Z, Mattiuzzi G, Estey E, et al. 2004. β-D-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 39:199-205
94. Kato A, Takita T, Furuhashi M, et al. 2001. Elevation of blood (1→3)-beta-D-glucan concentrations in hemodialysis patients. Nephron 89:15-19
95. Digby J, Kalbfleisch J, Glenn A, et al. 2003. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin. Diag. Lab. Immunol. 10:882-85
96. White P, Archer A, Barnes R. 2005. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J. Clin. Microbiol. 43:2181-87
97. White P, Linton C, Perry M, et al. 2006. The evolution and evaluation of a whole blood polymerase chain reaction for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin. Infect. Dis. 42:479-86
98. Costa C, Costa JM, Desterke C, et al. 2002. Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J. Clin. Microbiol. 40:2224-27
99. Schabereiter-Gurtner C, Selitsch B, Rotter M, et al. 2007. Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens. J. Clin. Microbiol. 45:906-14